ClinicalTrials.gg
RecruitingNCT07228078Updated Nov 13, 2025

Open-Label Extension Protocol to SNK01-AD01 Study

A Phase 2 interventional study of SNK01 in Alzheimer Disease, sponsored by NKGen Biotech, Inc.. Recruiting at 1 site in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-13.

Sponsored by NKGen Biotech, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2025, registered Nov 2025).
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
1,147th of 1,609
30 · median 73
Started
2025
with 98 others
Phase 2
360 of 1,940
50 open now
Primary completion
2028-04
later than 294 of 444 live
Registered
1,860th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,147th largest by planned enrollment of the 1,609 interventional ones that give a count, is one of 99 that started in 2025, is one of 360 in phase 2, reaches primary completion later than 294 of the 444 other live ones, and was the 1,860th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

Open-Label Extension Protocol to SNK01-AD01 Study

Read the detailed description

Open-label extension study to assess long-term safety and tolerability of SNK01 administered as an intravenous (IV) infusion every 3 weeks in participants with Alzheimer's Disease

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Moderate Alzheimer's Disease
  • AD
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will be considered eligible for participation in the study if all the following criteria are satisfied:

  • The participant or their legally authorized representative must be willing and able to give their in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the subject).
  • Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site.
  • Participants previously completed participation in study SNK01-AD01.

Exclusion criteria

Exclusion Criteria:

Participants who fulfill any of the following criteria will not be recruited into the study:

  • Any participant whose safety the investigator considers to be at risk from this trial's intervention.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Open-Label

    SNK01

    Biological: SNK01

Interventions

  • BiologicalSNK01

    SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs

    Time frame: 1 Year

Secondary outcomes

  1. Preliminary efficacy in cognitive assessment scores of CDR-SB

    Measure changes in cognitive assessment of CDR-SB from baseline

    Time frame: 1 Year

  2. Preliminary efficacy in cognitive assessment scores of MMSE

    Measure changes in cognitive assessment of MMSE from baseline

    Time frame: 1 Year

  3. Preliminary efficacy in cognitive assessment scores of NPI

    Measure changes in cognitive assessment of NPI from baseline

    Time frame: 1 Year

  4. Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe

    Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline

    Time frame: 1 Year

  5. Preliminary efficacy in cognitive assessment scores of ADAS-Cog

    Measure changes in cognitive assessment of ADAS-Cog from baseline

    Time frame: 1 Year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2028, 34 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 34 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Nov 13, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Nov 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07228078
Lead sponsor
NKGen Biotech, Inc.
Responsible party
Sponsor
First posted
Nov 13, 2025
Start date
Jun 30, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 13, 2025

Study contacts

Study Director
Contact
trials@nkgenbiotech.com
949-396-6830

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Troculeucel

Start the discussion